Once-Daily Administration of Pentasa in Remission Phase Approved; Kyorin Pharmaceutical

August 27, 2012
Kyorin Holdings announced on August 24 that Kyorin Pharmaceutical’s ulcerative colitis treatment Pentasa Tablets 250 mg and 500 mg (mesalazine) obtained approval for a new dosage (once-daily administration for ulcerative colitis in remission phase) on the same day. The daily...read more